Health News Roundup: Key Developments in Pharmaceuticals, Policies, and Trials

This article summarizes recent health news, covering topics such as Washington state's abortion pill stockpile, Amgen's drug meeting its goals, FDA approval of IntraBio's drug, BioAge Labs' IPO, Merck's trial failure, Pfizer vs. Moderna patent battle, 2seventy Bio's trial halt, and developments in the vaping industry.

Following is a summary of current health news briefs.

Washington state's first-in-the-nation stockpile of abortion drugs is set to act as a safeguard against any future lawsuits or political changes that might challenge abortion rights nationwide, per Governor Jay Inslee. Last year, Inslee ordered the purchase of 30,000 doses of mifepristone to ensure ongoing access.

Amgen's recent study revealed that its experimental drug showed promise in improving daily activities for patients with a rare muscular disorder, successfully meeting its primary objectives in a late-stage clinical trial. The drug aims to benefit those suffering from myasthenia gravis, a debilitating muscle-weakening condition.

The U.S. FDA has given the green light to IntraBio's new medication designed for Niemann-Pick disease type C, a rare genetic disorder. This approval follows closely on the heels of the first-ever treatment for the disease gaining approval, signaling progress in the fight against such fatal conditions.

In financial developments, BioAge Labs aims for a significant valuation in an expanded IPO, hoping to capitalize on investor interest, particularly in the obesity drug sector. Concurrently, Merck announced a setback in its colorectal cancer therapy trial, finding that its drug failed to meet primary survival goals in recent tests.

The legal showdown between Pfizer and Moderna over COVID-19 vaccine patents is set to escalate, with London's High Court granting Pfizer permission to take the dispute to the Court of Appeal. This decision ensures that the ongoing patent battle will continue to unfold in the legal arena.

2seventy Bio has decided to halt patient enrollment in a key blood cancer therapy study amid a changing treatment landscape. The company's Abecma therapy faces increasing competition and a shrinking pool of eligible patients, prompting this strategic shift.

KKR and GIC are making moves to offload their stakes in Metro Pacific Health, engaging major banks to facilitate a sale that could value the company at $3.2 billion. This potential sale marks a significant shift for the Philippine healthcare provider.

In the vaping industry, top Chinese companies are exploring nicotine alternatives, including synthetic compounds like 6-methyl nicotine. While these alternatives may offer new product opportunities, health experts caution that their long-term impacts require thorough investigation.

Senator Bernie Sanders has secured commitments from top pharmacy benefit managers, ensuring expanded coverage for Novo Nordisk's weight-loss drugs if price reductions are met. This development follows Sanders' advocacy for more affordable medication options at a Senate committee hearing.